Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Atossa Therapeutics, retaining the price target of $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on Atossa Therapeutics’ strategic adjustments to their Phase 2 EVANGELINE trial, which are designed to optimize clinical outcomes while conserving financial resources. The trial’s redesign reduces the patient count significantly, which is expected to save substantial costs and extend the company’s financial runway. This allows Atossa to focus on NDA-enabling activities for breast cancer risk reduction, a move that is seen as both financially prudent and strategically focused.
Additionally, the promising clinical data from the EVANGELINE trial presented at SABCS further supports the potential of Z-endoxifen as an alternative treatment for breast cancer. The data showed a strong efficacy signal at an 80 mg dose, with a high response rate comparable to existing treatments. These findings validate the company’s approach and support further investigation, contributing to the positive outlook and the Buy rating given by Emily Bodnar.
In another report released on October 2, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.